This study is conducted in Asia. The aim of this observational study is to evaluate the safety and tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the treatment of Filipino patients with Type 1 and Type 2 Diabetes Mellitus.

Inclusion Criteria:

• Patients diagnosed with Type 1 or Type 2 Diabetes Mellitus.
• Newly diagnosed insulin naive patients
• Patients currently on human insulin or on basal insulin
• Patients prescribed with Levemir™ FlexPen™ (Insulin Detemir) therapy
• Usage should be in accordance with the current prescribing information (See attached prescribing information)

Exclusion Criteria:

• Previous history of hypersensitivity to Insulin Detemir (Levemir™) and its excipients (See attached prescribing information)
• Contraindications and warnings specified in the current prescribing information (See attached prescribing information)
• Pregnant women, those planning to become pregnant, or women who are breastfeeding
• Patients who are already on human premix or premix analogue (unless they are going to be shifted to basal-bolus therapy)
• Children below 6 years old

Patients with Type 1 and Type 2 Diabetes